Stryker Reports Strong Q4 Results, 2026 EPS Guidance Meets Consensus
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 29 2026
0mins
Should l Buy SYK?
Source: seekingalpha
- Strong Earnings Beat: Stryker reported Q4 non-GAAP EPS of $4.47, exceeding expectations by $0.07, reflecting robust performance in the medtech sector.
- Sales Growth Momentum: The company achieved a 17.5% year-over-year sales increase in its MedSurg and Neurotechnology segments, while the Orthopaedics division grew modestly by 2.2%, indicating solid growth across multiple business areas.
- Healthy Cash Position: As of 2025, Stryker's cash and cash equivalents stood at approximately $4 billion, up from $3.7 billion on December 31, 2024, enhancing the company's financial flexibility.
- Optimistic Future Guidance: Stryker projects non-GAAP EPS for 2026 in the range of $14.90 to $15.10, aligning with the consensus of $14.94, and anticipates organic net sales growth of 8% to 9.5%, demonstrating confidence in future performance.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SYK?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SYK
Wall Street analysts forecast SYK stock price to rise
20 Analyst Rating
17 Buy
3 Hold
0 Sell
Strong Buy
Current: 315.130
Low
390.00
Averages
430.32
High
465.00
Current: 315.130
Low
390.00
Averages
430.32
High
465.00
About SYK
Stryker Corporation is a medical technology company. The Company offers products and services in MedSurg, Neurotechnology and Orthopaedics that help improve patient and healthcare outcomes. Its segments include MedSurg and Neurotechnology and Orthopaedics. Its MedSurg products include surgical equipment, patient and caregiver safety technologies, and navigation systems (Instruments), endoscopic and communications systems (Endoscopy), and patient handling, emergency medical equipment, intensive care disposable products and clinical communication and artificial intelligence-assisted virtual care platform technology (Medical). Neurotechnology includes neurosurgical, neurovascular and craniomaxillofacial implant products. Its Orthopaedics primarily include implants used in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries. The Company also offers solutions for venous thromboembolism clot removal without the use of thrombolytic drugs.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Stryker Q1 2026 Earnings Call Insights
- Cyber Incident Impact: CEO Kevin Lobo stated that the cyber incident significantly impacted Q1 results, causing distortions that are expected to normalize over the year, demonstrating the company's resilience in crisis management.
- Sales Growth Performance: Despite the cyber incident, Stryker reported organic sales growth of 2.4% in Q1, with 1.9% growth in the U.S. and 3.9% internationally, indicating strong demand across global markets.
- Acquisition Plans: Stryker announced its agreement to acquire Amplitude Vascular Systems, expected to close in Q2, which will expand treatment options for peripheral vascular customers and enhance its competitive position in the cardiovascular market.
- Financial Outlook: Despite challenges, Stryker maintains its full-year guidance for 2026, projecting organic net sales growth between 8% and 9.5% and adjusted earnings per share between $14.90 and $15.10, reflecting management's confidence in future performance.
See More
Stryker Reports Miss on Both Revenue and Earnings in Q1
- Earnings Miss: Stryker reported a miss on both revenue and earnings in its Q1 2024 results, with revenue at $6 billion reflecting only a 2.6% year-over-year increase, indicating potential weakness in market demand that could affect investor confidence going forward.
- Decline in EPS: The adjusted EPS of $2.60 fell from $2.84 year-over-year, missing expectations by $0.38, which highlights challenges in cost management and profitability that the company is currently facing.
- Cash Flow Concerns: As of March 31, 2026, Stryker's cash and cash equivalents stood at approximately $2.9 billion, down from $4 billion on December 31, 2025, suggesting a need for improved liquidity management to navigate future uncertainties.
- Guidance Maintained: Despite the disappointing Q1 performance, Stryker has maintained its 2026 EPS guidance of $14.90 to $15.10, reflecting confidence in long-term growth prospects, with organic sales growth projected between 8% and 9.5%.
See More
Stryker Misses Q1 Profit and Revenue Estimates Amid Cyberattack
- Profit Outlook Maintained: Stryker reiterated its full-year adjusted profit outlook of $14.90 to $15.10 per share, despite missing first-quarter profit and revenue estimates, demonstrating resilience amid soft market demand.
- Revenue Decline: The company reported total revenue of $6.02 billion for the first quarter, falling short of analysts' expectations of $6.35 billion, primarily impacted by weakened demand for complex surgical devices, reflecting challenges in the medical device market.
- Segment Performance: Sales in the medical surgery and neurotechnology segment rose 5% to $3.21 billion but missed the $3.83 billion forecast, while the orthopedics segment saw a 6.3% increase to $2.81 billion, exceeding the $2.51 billion expectation, indicating varied performance across business lines.
- Cyberattack Impact: Stryker faced a cyberattack in March attributed to the Iranian-linked group Handala, causing operational disruptions and limited system access; although the company could not verify related social media claims, this incident likely added pressure to its business operations.
See More
Stryker's Q1 Earnings Impacted by Cyber Incident
- Cyber Incident Impact: Stryker faced a cyber incident in Q1 that disrupted global operations, and while the company was fully operational by early April, this event significantly affected sales and revenue recognition, with anticipated repercussions on annual performance.
- Organic Sales Growth: The company reported a 2.4% organic sales growth for Q1, with 1.9% growth in the U.S. and 3.9% internationally, and despite the cyber incident's impact, Stryker remains optimistic about market fundamentals and has maintained its full-year guidance.
- Acquisition Plans: Stryker announced the acquisition of Amplitude Vascular Systems, expected to close in Q2, which will expand treatment options for peripheral vascular customers and enhance its presence in the cardiovascular market.
- New Business Integration: The company established its Orthotech business in Q1 by combining Mako and Enabling Technologies with its orthopedic instruments portfolio, aiming to simplify customer experience, accelerate innovation, and improve market responsiveness, aligning with long-term strategic goals.
See More
Four Tech Giants Boost Capital Expenditure Amid AI Race
- Market Performance: On the last day of April, the S&P 500 index surpassed 7,200 for the first time, achieving an all-time high with a more than 10% increase for the month, reflecting optimistic market sentiment regarding economic recovery.
- Significant Capex Increase: The four tech giants—Alphabet, Amazon, Microsoft, and Meta—are projected to spend a total of $695 billion in capital expenditures this year, marking a more than 14% increase from the previous estimate of $608 billion, highlighting their fierce competition in the AI sector.
- Divergent Stock Reactions: Despite all four companies increasing their spending, Alphabet's stock surged nearly 10% to a new high, while Meta's stock fell almost 8%, indicating differing market perceptions regarding their cloud business strategies.
- Apple's Upcoming Earnings Report: Apple is set to release its earnings report following CEO Tim Cook's announcement of his resignation in September, with market focus on new CEO John Ternus's strategic direction and its potential impact on product pricing and supply chain issues.
See More
Medtronic Cyberattack Does Not Affect Products or Operations
- Cyberattack Overview: Medtronic experienced a cyberattack last week, but the company confirmed that the incident did not impact its products, patient safety, or manufacturing and distribution operations, demonstrating effective isolation of its IT network from product support systems.
- Business Impact Assessment: While the cyberattack raises concerns about the growing cyber risks for medical device manufacturers, Medtronic expects that the incident will not materially impact its business or financial results, indicating operational resilience.
- Industry Context: In contrast, competitor Stryker reported a destructive cyberattack last month that delayed surgeries and caused widespread business disruption, highlighting the cybersecurity challenges faced by the healthcare industry.
- Response Measures: Medtronic has activated its emergency response plans and engaged cybersecurity experts to help contain the attack, reflecting the company's proactive approach to addressing cyber threats.
See More
Stryker Q1 2026 Earnings Call Insights
- Cyber Incident Impact: CEO Kevin Lobo stated that the cyber incident significantly impacted Q1 results, causing distortions that are expected to normalize over the year, demonstrating the company's resilience in crisis management.
- Sales Growth Performance: Despite the cyber incident, Stryker reported organic sales growth of 2.4% in Q1, with 1.9% growth in the U.S. and 3.9% internationally, indicating strong demand across global markets.
- Acquisition Plans: Stryker announced its agreement to acquire Amplitude Vascular Systems, expected to close in Q2, which will expand treatment options for peripheral vascular customers and enhance its competitive position in the cardiovascular market.
- Financial Outlook: Despite challenges, Stryker maintains its full-year guidance for 2026, projecting organic net sales growth between 8% and 9.5% and adjusted earnings per share between $14.90 and $15.10, reflecting management's confidence in future performance.
See More
Stryker Reports Miss on Both Revenue and Earnings in Q1
- Earnings Miss: Stryker reported a miss on both revenue and earnings in its Q1 2024 results, with revenue at $6 billion reflecting only a 2.6% year-over-year increase, indicating potential weakness in market demand that could affect investor confidence going forward.
- Decline in EPS: The adjusted EPS of $2.60 fell from $2.84 year-over-year, missing expectations by $0.38, which highlights challenges in cost management and profitability that the company is currently facing.
- Cash Flow Concerns: As of March 31, 2026, Stryker's cash and cash equivalents stood at approximately $2.9 billion, down from $4 billion on December 31, 2025, suggesting a need for improved liquidity management to navigate future uncertainties.
- Guidance Maintained: Despite the disappointing Q1 performance, Stryker has maintained its 2026 EPS guidance of $14.90 to $15.10, reflecting confidence in long-term growth prospects, with organic sales growth projected between 8% and 9.5%.
See More
Stryker Misses Q1 Profit and Revenue Estimates Amid Cyberattack
- Profit Outlook Maintained: Stryker reiterated its full-year adjusted profit outlook of $14.90 to $15.10 per share, despite missing first-quarter profit and revenue estimates, demonstrating resilience amid soft market demand.
- Revenue Decline: The company reported total revenue of $6.02 billion for the first quarter, falling short of analysts' expectations of $6.35 billion, primarily impacted by weakened demand for complex surgical devices, reflecting challenges in the medical device market.
- Segment Performance: Sales in the medical surgery and neurotechnology segment rose 5% to $3.21 billion but missed the $3.83 billion forecast, while the orthopedics segment saw a 6.3% increase to $2.81 billion, exceeding the $2.51 billion expectation, indicating varied performance across business lines.
- Cyberattack Impact: Stryker faced a cyberattack in March attributed to the Iranian-linked group Handala, causing operational disruptions and limited system access; although the company could not verify related social media claims, this incident likely added pressure to its business operations.
See More
Stryker's Q1 Earnings Impacted by Cyber Incident
- Cyber Incident Impact: Stryker faced a cyber incident in Q1 that disrupted global operations, and while the company was fully operational by early April, this event significantly affected sales and revenue recognition, with anticipated repercussions on annual performance.
- Organic Sales Growth: The company reported a 2.4% organic sales growth for Q1, with 1.9% growth in the U.S. and 3.9% internationally, and despite the cyber incident's impact, Stryker remains optimistic about market fundamentals and has maintained its full-year guidance.
- Acquisition Plans: Stryker announced the acquisition of Amplitude Vascular Systems, expected to close in Q2, which will expand treatment options for peripheral vascular customers and enhance its presence in the cardiovascular market.
- New Business Integration: The company established its Orthotech business in Q1 by combining Mako and Enabling Technologies with its orthopedic instruments portfolio, aiming to simplify customer experience, accelerate innovation, and improve market responsiveness, aligning with long-term strategic goals.
See More
Four Tech Giants Boost Capital Expenditure Amid AI Race
- Market Performance: On the last day of April, the S&P 500 index surpassed 7,200 for the first time, achieving an all-time high with a more than 10% increase for the month, reflecting optimistic market sentiment regarding economic recovery.
- Significant Capex Increase: The four tech giants—Alphabet, Amazon, Microsoft, and Meta—are projected to spend a total of $695 billion in capital expenditures this year, marking a more than 14% increase from the previous estimate of $608 billion, highlighting their fierce competition in the AI sector.
- Divergent Stock Reactions: Despite all four companies increasing their spending, Alphabet's stock surged nearly 10% to a new high, while Meta's stock fell almost 8%, indicating differing market perceptions regarding their cloud business strategies.
- Apple's Upcoming Earnings Report: Apple is set to release its earnings report following CEO Tim Cook's announcement of his resignation in September, with market focus on new CEO John Ternus's strategic direction and its potential impact on product pricing and supply chain issues.
See More
Medtronic Cyberattack Does Not Affect Products or Operations
- Cyberattack Overview: Medtronic experienced a cyberattack last week, but the company confirmed that the incident did not impact its products, patient safety, or manufacturing and distribution operations, demonstrating effective isolation of its IT network from product support systems.
- Business Impact Assessment: While the cyberattack raises concerns about the growing cyber risks for medical device manufacturers, Medtronic expects that the incident will not materially impact its business or financial results, indicating operational resilience.
- Industry Context: In contrast, competitor Stryker reported a destructive cyberattack last month that delayed surgeries and caused widespread business disruption, highlighting the cybersecurity challenges faced by the healthcare industry.
- Response Measures: Medtronic has activated its emergency response plans and engaged cybersecurity experts to help contain the attack, reflecting the company's proactive approach to addressing cyber threats.
See More
